Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors

International Journal of Cancer

Volumn 106, Issue 6, 2003, Pages 887-895

  Wardelmann, Eva ^a,c   Losen, Inge ^a   Hans, Volkmar ^a   Neidt, Iris ^a   Speidel, Nicola ^a   Bierhoff, Erhard ^b   Heinicke, Thomas ^a   Pietsch, Torsten ^a   Büttner, Reinhard ^a   Merkelbach Bruse, Sabine ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Department of Pathology ^*  (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

c kit mutation; Exon 11; Gastrointestinal stromal tumor; Predictive marker

Indexed keywords

AMINO ACID; LYSINE; STEM CELL FACTOR; TRYPTOPHAN;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CODON; EXON; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GERMANY; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE C KIT; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RISK FACTOR; SEQUENCE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; CARCINOMA; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXONS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; LYSINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SEQUENCE DELETION; SEQUENCE HOMOLOGY, AMINO ACID; STROMAL CELLS; SURVIVAL RATE; TRYPTOPHAN;

EID: 0042338788     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11323     Document Type: Article

References (45)

1. Miettinen M, Virolainen M, Sarlomo-Rikkala M. Gastrointestinal stromal tumors: value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995;19:207-16.
2. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11:728-34.
3. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
4. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LJ, Tervahartiala P, Tuveson DA, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
5. van Osteroom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, van Glabbeke M, Silberman S, Nielsen OS. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001;358:1421-3.
6. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-20.
7. Moskaluk CA, Tian Q, Marshall CR, Rumpel CA, Franquemont DW, Frierson HF. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene 1999;18:1897-902.
8. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21.
9. Wardelmann E, Neidt I, Bierhoff E, Speidel N, Manegold C, Fischer HP, Pfeifer U, Pietsch T. c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol 2002;15:125-36.
10. Andersson LJ, Sjögren H, Meis-Kindblom JM, Stenman G, Aman P, Kindblom LG. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002;160:15-22.
11. Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, Kitamura Y. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001;193:505-10.
12. Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, Sobin LH, Miettinen M. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. Am J Pathol 2000;157:1091-5.
13. Ma Y, Cunningham ME, Wang X, Ghosh I, Regan L, Longley BJ. Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular justamembrane region. J Biol Chem 1999;19:13399-402
14. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol 2001;32:578-82.
15. Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O'Leary TJ. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998;78:1633-6.
16. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:53-60.
17. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H, Kitamura Y. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999;59:4297-300.
18. Sakurai S, Fukasawa T, Chong JM, Tanaka A, Fukayama M. C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal). Jpn J Cancer Res 1999;90:1321-8.
19. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD, Fletcher JA. Prognostic value of KIT mutation type, mitotic activity, and histological subtype in gastrointestinal stromal tumors. J Clin Oncol 2002;20:3898-905.
20. Fletcher CD, Berman J, Corless CL, Gorstein F, Lasota J, Longley B, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-65.
21. Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478-83.
22. Merkelbach S, Gehlen J, Handt S, Füzesi L. Novel enzyme immunoassay and optimized DNA extraction for the detection of polymerasechain-reaction-amplified viral DNA from paraffin-embedded tissue. Am J Pathol 1997;150:1537-46.
23. Mazur MT, Clark HB. Gastric stromal tumors. Am J Surg Pathol 1983;7:507-19
24. Appelman HD. Smooth muscle tumors of the gastrointestinal tract: what we know now that Stout didn't know. Am J Surg Pathol 1986;10:83-99.
25. Pike AM, Lloyd RV, Appelman HD. Cell markers in gastrointestinal stromal tumors. 1988;19:830-4.
26. Franquemont DW, Frierson HF. Muscle differentiation and clinicopathological features of gastrointestinal stromal tumors. Am J Surg Pathol 1992;16:947-54.
27. van de Rijn M, Hendrickson MR, Rouse RV. CD34 expression by gastrointestinal stromal tumors. Hum Pathol 1994:25:766-71.
28. Monihan JM, Carr NJ, Sobin LH. CD34 immunoexpression in stromal tumours of the gastrointestinal tract and in mesenteric fibromatoses. Histopathology 1994;25:469-73.
29. Cunningham RE, Federspiel BH, McCarthy WF, Sobin LH, O'Leary TJ. Predicting prognosis of gastrointestinal smooth muscle tumors. Role of clinical and histological evaluation, flow cytometry, and image cytometry. Am J Surg Pathol 1993;17:588-94.
30. Rudolph P, Gloeckner K, Parwaresch R, Harms D, Schmidt D. Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathological study. Hum Pathol 1998;29:791-800.
31. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Miettinen M, Knuutila S. High-resolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor supressor loci. Genes Chromosomes Cancer 2000;27:387-91.
32. El-Rifai W, Sarlomo-Rikala M, Miettinen M, Knuutila S, Andersson LC. DNA copy number losses in chromosome 14: an early change in gastrointestinal stromal tumors. Cancer Res 1996;56:3230-3.
33. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Miettinen M, Knuutila S. DNA copy number changes in gastrointestinal stromal tumors: a distinct genetic entity. Ann Chir Gynaecol 1998;87:287-90.
34. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 2000;60:3899-903.
35. Günther T, Schneider-Stock R, Häckel C, Pross M, Schulz H-U, Lippert H, Roessner A. Telomerase activity and expression of hTRT and hTR in gastrointestinal stromal tumors in comparison with extra-gastrointestinal sarcomas. Clinical Cancer Research 2000;6:1811-8.
36. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors of survival. Ann Surg 2000;231:51-8.
37. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995;103:41-7.
38. Franquemont DW, Frierson HF. Proliferation cell nuclear antigen immunoreactivity and prognosis in gastrointestinal stromal tumors. Mod Pathol 1995;8:473-7.
39. Corless CL, Mc Greevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-72.
40. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 2000;24:211-22.
41. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical and molecular genetic study of 44 cases. Am J Surg Pathol 2000;24:1339-52.
42. Lee JR, Joshi V, Griffin JD, Lasota J, Miettinen M. Gastrointestinal autonomic nerve tumor - Immunohistochemical and molecular identity with gastrointestinal stromal tumor. Am J Surg Pathol 2001;25:979-87.
43. Li SQ, O'Leary TJ, Sobin LH, Erozan YS, Rostenthal DL, Przygodzki RM. Analysis of KIT mutation and protein expression in fine needle aspirates of gastrointestinal stromal/smooth muscle tumors. Acta Cytol 2000;44:981-6.
44. Linnekin D, DeBerry CS, Mou S. Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J Biol Chem 1997;272:27450-5.
45. Kozlowski M, Larose L, Lee F, Le DM, Rottapel R, Siminovitch KA. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol Cell Biol 1998;18:2089-99.